STAAR Surgical (NASDAQ:STAA) Shares Sold by Trexquant Investment LP

Trexquant Investment LP trimmed its position in shares of STAAR Surgical (NASDAQ:STAA - Free Report) by 62.1% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 51,697 shares of the medical instruments supplier's stock after selling 84,603 shares during the quarter. Trexquant Investment LP owned 0.10% of STAAR Surgical worth $1,256,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently bought and sold shares of STAA. Quarry LP purchased a new stake in STAAR Surgical during the 3rd quarter worth approximately $50,000. Illinois Municipal Retirement Fund increased its position in shares of STAAR Surgical by 8.3% during the fourth quarter. Illinois Municipal Retirement Fund now owns 30,144 shares of the medical instruments supplier's stock worth $732,000 after acquiring an additional 2,318 shares during the period. FMR LLC raised its stake in shares of STAAR Surgical by 79.3% in the third quarter. FMR LLC now owns 7,092 shares of the medical instruments supplier's stock valued at $263,000 after acquiring an additional 3,136 shares in the last quarter. Generali Investments Towarzystwo Funduszy Inwestycyjnych boosted its holdings in STAAR Surgical by 9.7% in the fourth quarter. Generali Investments Towarzystwo Funduszy Inwestycyjnych now owns 39,500 shares of the medical instruments supplier's stock valued at $959,000 after purchasing an additional 3,500 shares during the period. Finally, HighTower Advisors LLC increased its holdings in STAAR Surgical by 42.6% during the 4th quarter. HighTower Advisors LLC now owns 12,956 shares of the medical instruments supplier's stock worth $315,000 after purchasing an additional 3,871 shares during the period. 96.70% of the stock is currently owned by hedge funds and other institutional investors.

Remove Ads

Insider Activity

In other STAAR Surgical news, major shareholder Broadwood Partners, L.P. acquired 497,631 shares of the company's stock in a transaction on Friday, April 4th. The shares were bought at an average cost of $15.91 per share, for a total transaction of $7,917,309.21. Following the completion of the purchase, the insider now owns 13,194,210 shares in the company, valued at $209,919,881.10. This trade represents a 3.92 % increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. Over the last ninety days, insiders bought 1,750,802 shares of company stock valued at $28,584,295. 1.00% of the stock is currently owned by company insiders.

STAAR Surgical Trading Down 0.5 %

Shares of NASDAQ STAA traded down $0.09 during trading hours on Tuesday, reaching $17.18. The stock had a trading volume of 136,805 shares, compared to its average volume of 787,720. The firm has a market cap of $847.40 million, a price-to-earnings ratio of -41.80 and a beta of 0.75. STAAR Surgical has a fifty-two week low of $13.50 and a fifty-two week high of $50.00. The firm has a 50-day moving average of $17.53 and a 200-day moving average of $23.80.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on STAA. Stifel Nicolaus cut their target price on shares of STAAR Surgical from $38.00 to $20.00 and set a "buy" rating on the stock in a research note on Wednesday, February 12th. Piper Sandler reduced their price objective on shares of STAAR Surgical from $40.00 to $16.00 and set a "neutral" rating on the stock in a report on Wednesday, February 12th. Mizuho downgraded shares of STAAR Surgical from an "outperform" rating to a "neutral" rating and lowered their target price for the stock from $45.00 to $17.00 in a research note on Wednesday, February 12th. StockNews.com cut STAAR Surgical from a "hold" rating to a "sell" rating in a research note on Thursday, February 13th. Finally, Jefferies Financial Group cut STAAR Surgical from a "buy" rating to a "hold" rating in a research report on Wednesday, February 12th. Two research analysts have rated the stock with a sell rating, eight have given a hold rating and one has issued a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average target price of $25.29.

STAAR Surgical Company Profile

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.